Angiotensin system modulation in focal segmental glomerulosclerosis: pharmacological basis and clinical implications
New therapies, including dual AT1/endothelin-A antagonism and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes, while biomarker-driven strategies may enable more tailored treatment, although their clinical impact remains...